disease interaction(s) of atrial fibrillation with myocardial infarction
Jump to navigation
Jump to search
Management
- patients with atrial fibrillation & coronary artery disease often need dual anticoagulation & anti-platelet therapy[1]
- the combination of direct oral anticoagulant + P2Y12 inhibitor is as effective as anticoagulant + P2Y12 inhibitor + aspirin in preventing myocardial ischemia with less bleeding[1][2][3]
More general terms
References
- ↑ 1.0 1.1 1.2 Lamberts M et al. Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention. J Am Coll Cardiol 2013 Sep 10; 62:981 PMID: https://www.ncbi.nlm.nih.gov/pubmed/23747760
Markowitz SM. Antithrombotic regimens in patients with atrial fibrillation and coronary disease: Optimizing efficacy and safety. J Am Coll Cardiol 2013 Sep 10; 62:990. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23747772 - ↑ 2.0 2.1 Link MS Which Anticoagulation Strategy for Patients with Atrial Fibrillation and a New Stent? NEJM Journal Watch. Nov 14, 2016 Massachusetts Medical Society (subscription needed) http://www.jwatch.org
Gibson CM, Mehran R, Bode C et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016 Nov 14 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27959713 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1611594 - ↑ 3.0 3.1 Cannon CP, Bhatt DL, Oldgren J, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 2017; 377:1513-1524. October 19, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28844193 <Internet> http://www.nejm.org/doi/10.1056/NEJMoa1708454